Towards a consensus roadmap for a new diagnostic framework for mental disorders
Current nosology claims to separate mental disorders into distinct categories that do not overlap with each other. This nosological separation is not based on underlying pathophysiology but on convention-based clustering of qualitative symptoms of disorders which are typically measured subjectively. Yet, clinical heterogeneity and diagnostic overlap in disease symptoms and dimensions within and across different diagnostic categories of mental disorders is huge. While diagnostic categories provide the basis for general clinical management, they do not describe the underlying neurobiology that gives rise to individual symptomatic presentations. The ability to incorporate neurobiology into the diagnostic framework and to stratify patients accordingly will be a critical step forward for the development of new treatments for mental disorders. Furthermore, it will also allow physicians to provide patients with a better understanding of their illness's complexities and management. To realize this ambition, a paradigm shift is needed to build an understanding of how neuropsychiatric conditions can be defined more precisely using quantitative (multimodal) biological processes and markers and thus to significantly improve treatment success. The ECNP New Frontiers Meeting 2024 set out to develop a consensus roadmap for building a new diagnostic framework for mental disorders by discussing its rationale, outlook, and consequences with all stakeholders involved. This framework would instantiate a set of principles and procedures by which research could continuously improve precision diagnostics while moving away from traditional nosology. In this meeting report, the speakers' summaries from their presentations are combined to address three key elements for generating such a roadmap, namely, the application of innovative technologies, understanding the biology of mental illness, and translating biological understanding into new approaches. In general, the meeting indicated a crucial need for a biology-informed framework to establish more precise diagnosis and treatment for mental disorders to facilitate bringing the right treatment to the right patient at the right time.
Authors
- Matthew H. Hotopf (ORCID: https://orcid.org/0000-0002-3980-4466)
- Bruce N. Cuthbert (ORCID: https://orcid.org/0000-0003-0486-5872)
- Diego Hidalgo‐Mazzei (ORCID: https://orcid.org/0000-0002-2693-6849)
- Paris Alexandros Lalousis (ORCID: https://orcid.org/0000-0001-9642-3080)
- Hugh Marston (ORCID: https://orcid.org/0000-0002-7460-0581)
- Cathryn M. Lewis (ORCID: https://orcid.org/0000-0002-8249-8476)
- Martien J. Kas (ORCID: https://orcid.org/0000-0002-4471-8618)
- Quentin J. M. Huys (ORCID: https://orcid.org/0000-0002-8999-574X)
- Amit Etkin (ORCID: https://orcid.org/0000-0001-8259-3521)
- Livia De Picker (ORCID: https://orcid.org/0000-0002-6883-0559)
- Steven E. Hyman (ORCID: https://orcid.org/0000-0002-3628-2359)
- Leanne M. Williams (ORCID: https://orcid.org/0000-0001-9987-7360)
- Gemma Modinos
Institutions
- Broad Institute (US)
- Boehringer Ingelheim (Germany) (DE)
- University of Groningen (NL)
- King's College London (GB)
- Neurosciences Institute (US)
- Antwerp University Hospital (BE)
- Stanford Health Care (US)
- Stanford Medicine (US)
- Alto Neuroscience (United States) (US)
- University Psychiatric Hospital (SI)
- National Institute of Mental Health (CZ)
- University College London (GB)
- Ludwig-Maximilians-Universität München (DE)
- Camden and Islington NHS Foundation Trust (GB)
- Stanford University (US)
Publication Details
- Journal
- European Neuropsychopharmacology
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1016/j.euroneuro.2024.08.515
- Citations
- 10
- Primary Topic
- Mental Health Research Topics
- Type
- article
- Field-Weighted Citation Impact
- 5.08
Funders
- Medical Research Council